Navigation Links
Mylan Receives FDA Approval for Generic Version of Prostate Cancer Treatment Casodex(R)
Date:7/7/2009

PITTSBURGH, July 7 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has received approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Bicalutamide Tablets, 50 mg.

Bicalutamide Tablets are the generic version of AstraZeneca's prostate cancer treatment Casodex(R), which had total U.S. sales of approximately $322 million for the 12 months ending March 31 for the same strength, according to IMS Health. Mylan has begun to ship this product.

Currently, Mylan has 118 ANDAs pending FDA approval representing $82.8 billion in annual brand sales, according to IMS Health. Thirty-five of these pending ANDAs are potential first-to-file opportunities, representing $16.7 billion in annual brand sales, according to IMS Health.

Mylan Inc., which provides products to customers in more than 140 countries and territories, ranks among the leading diversified generics and specialty pharmaceutical companies in the world. The company maintains one of the industry's broadest -- and highest quality -- product portfolios, supported by a robust product pipeline; owns a controlling interest in the world's third largest active pharmaceutical ingredient manufacturer; and operates a specialty business focused on respiratory and allergy therapies. For more information, please visit www.mylan.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related biology technology :

1. Mylan Announces Strategic Collaboration with Biocon to Enter the Global Generic Biologics Market
2. Mylan Again Calls for an End to Authorized Generics During 180-Day Exclusivity Period
3. Mylan Receives Tentative FDA Approval for Generic Version of Singulair(R)
4. Mylans Matrix Selected by the Clinton HIV/AIDS Initiative and UNITAID as the Primary Supplier of Five Second-Line and Seven Pediatric HIV/AIDS Treatments
5. Mylans Matrix Receives First Tentative FDA Approval Under PEPFAR for Generic Truvada(R)
6. Mylan Confirms Four First-to-File Challenges
7. Shire Files Lawsuit Against Mylan for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patent
8. Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008
9. Shire Receives FOSRENOL Paragraph IV Notice Letters from Barr Laboratories and Mylan
10. Cephalon and Eurand File Patent Infringement Lawsuit Against Mylan Pharmaceuticals and Barr Pharmaceuticals
11. Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2009)... Michael R. Drapp, a 34-year veteran of ...trade; Technologies, a business development and in...the emerging nanotechnology space. The company al...ct as a nanotechnology incubator. , ...- Michael R. Drapp , a 34-year veteran of the hig...
(Date:11/30/2009)...W YORK, Nov. 30 The Mic...JFF) today announced $1.5 million in total awards ...ly disease-modifying therapies for Parkinson,s dis...roaches to Drug Discovery for Parkinson,s Disease ...ration, plc (NYSE: ELN ), a neuroscience-based b...
(Date:11/30/2009)... CHANGCHUN, China and LOS ANGELES, Nov. 30 /PRN...ticals, Inc. (OTC Bulletin Board: CYXN; ,China Yon... manufacturer, distributor and,retailer of pharmac... has,completed preparation for distribution of med...Chinese government recently formalized the nation,...
(Date:11/30/2009)...OSTON and COPENHAGEN, Nov. 30 Exiq...day that the Harvard Medical School ICCB-Longwood ... a MicroRNA Screening Center of Excellence. ICCB-..., and associated hospitals and institutions, for h...i libraries. ,, MicroRNAs are a novel class of ...
Breaking Biology Technology:Silicon Valley Veteran Launches New Venture on the “nanoEdge” of the Emerging Nanotechnology Revolution 2Silicon Valley Veteran Launches New Venture on the “nanoEdge” of the Emerging Nanotechnology Revolution 3Silicon Valley Veteran Launches New Venture on the “nanoEdge” of the Emerging Nanotechnology Revolution 4The Michael J. Fox Foundation Announces $1.5 Million in Funding to Advance Development of Drug Targets for Disease-Modifying Parkinson's Disease Treatments 2The Michael J. Fox Foundation Announces $1.5 Million in Funding to Advance Development of Drug Targets for Disease-Modifying Parkinson's Disease Treatments 3China Yongxin Pharmaceuticals Inc. to Distribute Medicines on the Essential Drug List 2China Yongxin Pharmaceuticals Inc. to Distribute Medicines on the Essential Drug List 3Exiqon Recognizes Harvard Medical School Core Facility as MicroRNA Screening Center of Excellence 2Exiqon Recognizes Harvard Medical School Core Facility as MicroRNA Screening Center of Excellence 3
...ompany Reports Quarterly Net Income of $536,000 , ...l, Inc. (OTC Bulletin Board: CCEL) (the "Company"... family cord blood banks, today announced results ...nsolidated revenues for the first quarter of fisca... approximately $4.2 million for the first quarter ...
... Millennium Bioceutics, announces the...Caplex, to cancer patients worldwide. Caplex con...by an Oncologist and Clinical Dietitian. Caplex n...prehensive source of the most effective anti-tumor...ccumulated from medical research. Impressive chang...
...ina, April 8 Sinobiopharma Pharmaceutical Group (...he appointment of Ms. Yan Tan as Director of Marke...n Pharmaceutical Co., Ltd., Netherlands. She serve...anon, which was recently sold to Schering-Plough. ...nagement roles at China National Medicines Corpora...
Other Biology Technology:Cryo-Cell International, Inc. Reports First Quarter 2009 Results 2Cryo-Cell International, Inc. Reports First Quarter 2009 Results 3Cryo-Cell International, Inc. Reports First Quarter 2009 Results 4Cancer Fighting Nutrition Supplement, Caplex, Offers Cancer Patients A New All-Natural Treatment Option 2Sinobiopharma, Inc. Appoints New Director of Marketing 2
(Date:11/26/2009)...eir impressive antlers, red deer have been caught ...,s antlers are much more than decorative. They are...lling. John Currey, from The University of York, U... of bone for over half a century and has become fa...rough a long-standing collaboration with Tomas Lan...
(Date:11/26/2009)...g, 27 November 2009 What are the bare essentials ... produce a cell that can survive on its own? Can w...derstand how an entire organism functions as a sys...entists in a partnership between the European Mole...many, and the Centre de Regulacio Genmica (CRG) in...
(Date:11/25/2009)...Bacteria don,t have easy lives. In addition to mam...have natural enemies called bacteriophages, viruse...ays. , Still, bacteria and another class of mic...treme environments such as deep-sea volcanic vents...y have a built-in defense system that helps protec...
Breaking Biology News(10 mins):Tough yet stiff deer antler is materials scientist's dream 2First-ever blueprint of a minimal cell is more complex than expected 2First-ever blueprint of a minimal cell is more complex than expected 3Researchers discover biological basis of 'bacterial immune system' 2Researchers discover biological basis of 'bacterial immune system' 3Cholesterol and Cancer 3A Answers and Some New Questions 60688 1Cholesterol and Cancer 3A Answers and Some New Questions 60688 2Cholesterol and Cancer 3A Answers and Some New Questions 60688 3Cholesterol and Cancer 3A Answers and Some New Questions 60688 4Cholesterol and Cancer 3A Answers and Some New Questions 60688 5Whistleblower Lawsuit Nets Record 2427 5 Million 60685 1Whistleblower Lawsuit Nets Record 2427 5 Million 60685 2Whistleblower Lawsuit Nets Record 2427 5 Million 60685 3BibsToGo com Answers 3A How Can a Traditional Baby Product Help Corporate America Look Better 3F 60682 1BibsToGo com Answers 3A How Can a Traditional Baby Product Help Corporate America Look Better 3F 60682 2
...University and Texas A & M University have discove...n to specific tissues in animals. In studies to d...ding cells, the group previously identified a regi...was able to mediate nuclear targeting of any plasm...oth muscle cells but in no other cell type. In th...
...at an FDA-approved drug reverses the brain dysfunc...s sclerosis complex (TSC). Because half of TSC pa... new hope for addressing learning disorders due to... in its online June 22 edition. , Using a mouse m...rug approved by the FDA to fight tissue rejection ...
... Webinar hosted by TorreyPines Therapeutics, Inc. ...g together industry experts to discuss the opport...e spasticity through the inhibition of the neurotr...d Chief Executive Officer, Neil Kurtz, M.D., will ...s by: , Tony Yaksh, Ph.D., Professor and Vice C...
Other Biology News:New paradigm for cell-specific gene delivery 2Drug reverses mental retardation caused by genetic disorder 2Treating chronic pain, migraine & muscle spasticity through inhibition of neurotransmitter glutamate 2Treating chronic pain, migraine & muscle spasticity through inhibition of neurotransmitter glutamate 3
10% Normal Goat Serum from Invitrogen
GeneRacer Kit with SuperScript II RT and Zero Blunt TOPO PCR Cloning kit for Sequencing from Invitrogen
Goat Anti-Mouse Wnt-9b Affinity Purified Polyclonal Antibody, Unconjugated from R&D Systems
Chloride Colorimetric Assay Kit, QuantiChrom from BioAssay Systems
Biology Products: